| |
BioIVT has expanded its cell & gene therapy supporting portfolio to include LEUKOMAX XL Fresh Leukopaks with a minimum of 15 billion total nucleated cell count per collection. Learn More >> 
|
|
Today’s Big NewsDec 4, 2024 |
| By Darren Incorvaia Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. The new partners aim to develop new splice modulators for multiple disease areas, including oncology, with Rgenta able to receive up to nearly $500 million biobucks per target. |
|
|
|
By Zoey Becker It will take a unique offering to make a significant dent in the multibillion-dollar obesity market. But Antag has some star power on its side, with GLP-1 co-discoverer Jens Holst, M.D., one of the biotech's co-founders. |
By Nick Paul Taylor GSK has terminated a phase 1/2 hepatitis B trial after the therapeutic vaccine regimen failed to meet the efficacy endpoint, denting the company’s hopes of creating a functional cure for the infectious disease. |
By Fraiser Kansteiner In a warning letter published Tuesday, the FDA scolded Applied Therapeutics on two counts related to its 47-patient study of govorestat in kids with classic galactosemia, specifically raising issues related to data deletion and a dosing error. The write-up was issued around the same time that the agency rejected govorestat's approval application. |
By Nick Paul Taylor GSK has made another trip to China to build out its antibody-drug conjugate pipeline, returning with an option on a preclinical Duality Biologics candidate that could ultimately cost the Big Pharma $1 billion. |
By Darren Incorvaia Human genetics biotech Maze Therapeutics has navigated the biotech world’s tricky fundraising landscape to land a $115 million series D round. |
By Gabrielle Masson After pausing work on a rare cancer asset, Relay Therapeutics is passing the baton to Elevar Therapeutics. The two have signed a deal worth up to $500 million biobucks that gives Elevar licensing rights to an investigational oral small molecule designed to treat solid tumors. |
By Darren Incorvaia Dune-inspired Arrakis Therapeutics has tested its spice—an RNA-targeting small molecule—in a mouse model of myotonic dystrophy type 1 (DM1), with the drug reversing the prolonged muscle contraction that is characteristic of the disease. |
By Paige Minemyer UnitedHealth Group abruptly ended its investor day event on Wednesday morning as news reports surfaced that the CEO of its health plan division had been fatally shot. |
By Kevin Dunleavy Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight. In the SURMOUNT-5 study, while participants taking Zepbound lost an average of 20.2% of their weight after 72 weeks, those on Wegovy lost 13.7% of their weight. |
By Darren Incorvaia Amsterdam-based health tech company myTomorrows is eyeing expansion into the Asia-Pacific region, opening an operations hub in India that will help match patients with clinical trials. |
By Conor Hale The project will look to combine separate AI technologies currently under development by both the Mayo Clinic and Philips, which the company said could one day aid radiographers in completing difficult heart scans with less training. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
Whitepaper We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
